Physician profile
Jules Pean
NPI 1164476602
$2,008.72
in general payments reported to CMS, 2019-2025
15 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.77 · 2020: $189 · 2021: $693 · 2022: $309 · 2023: $414 · 2024: $138 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.46 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $720.87 | 2021-2023 | Farxiga, Lokelma |
| Abbott Laboratories | $246.43 | 2021-2025 | Aveir |
| Impulse Dynamics (USA) INC. | $147.08 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $120.00 | 2021 | |
| Novo Nordisk INC | $117.60 | 2020 | |
| Pfizer INC. | $104.80 | 2022-2024 | |
| Boston Scientific Corporation | $97.58 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.52 | 2020-2022 | |
| Biotronik INC. | $72.36 | 2021 | |
| Medtronic, INC. | $65.58 | 2025 | Venaseal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.70 | 2022-2023 | Eliquis |
| Abiomed | $47.17 | 2024 | Impella |
| Medtronic Vascular, INC. | $41.38 | 2020 | |
| Merck Sharp & Dohme LLC | $16.88 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Pean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.